Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine‐mobilized blood

Flow cytometric DNA analysis was performed in combination with three‐colour immunological staining of cell surface antigens on density‐separated mononuclear cells (MNC) obtained from peripheral blood (PB) before, during and after cytokine stimulation of healthy adults. The aim of the study was to determine the cell‐cycling status of haemopoietic progenitor cells mobilized into the blood of healthy volunteers during a 5 d treatment period with 5 μg per kg body weight of either granulocyte colony‐stimulating factor (G‐CSF) or granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Despite considerably increasing numbers of CD34+ PB MNC, the latter were not found to be in S/G2M phase, whereas, among the CD34− MNC, the proportion of cells in S/G2M phase increased from <0.1% to 0.75 ± 0.4% (GM‐CSF) and to 1.34 ± 0.75% (G‐CSF) and dropped again after discontinuation of the cytokine stimulation. These cells expressed CD33 but were negative for CD45RA, CD3, CD19 and CD14 and were thus considered granulopoietic cells. Analogous results were obtained from analyses of cord blood (CB). In contrast, CD34+ cells from bone marrow (BM) were partially (between 9% and 15%) found to be in S/G2M phase. The non‐cycling status of PB and CB progenitor cells was confirmed by the analysis of CD34+ cells enriched from the two cell sources. However, in vitro stimulation of these progenitor cells using IL3, GM‐CSF, erythropoietin and steel factor (SF) revealed that, after 48 h in suspension culture, up to 30% of the CD34+ cells were in S/G2M phase. The fact that cycling CD34+ cells are only detectable in BM but not in PB or CB may suggest different adhesive properties of migrating/mobilized ‘stem cells’ which may require the BM micro‐environment for adequate proliferation in vivo

[1]  L. To,et al.  A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. , 1994, Blood.

[2]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[3]  O. Haas,et al.  Peripheral blood hematopoietic progenitor cells of cytokine-stimulated healthy donors as an alternative for allogeneic transplantation. , 1994, Blood.

[4]  E. Wintersberger,et al.  Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.

[5]  W. Vainchenker,et al.  Erroneous results of 3H-thymidine incorporation are related to position of thymidine residues in oligodeoxynucleotides. , 1994, Experimental hematology.

[6]  R. V. van Oers,et al.  Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. , 1993, Blood.

[7]  O. Majdic,et al.  Myeloperoxidase expression in CD34+ normal human hematopoietic cells. , 1993, Blood.

[8]  D. Printz,et al.  Use of flow cytometric CD34 analysis to quantify hematopoietic progenitor cells. , 1993, Leukemia & lymphoma.

[9]  N. Russell,et al.  Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation , 1993, The Lancet.

[10]  C. Mache,et al.  Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers. , 1993, Bone marrow transplantation.

[11]  Y. Niitsu,et al.  Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. , 1993, Bone marrow transplantation.

[12]  S. Nimer The use of colony-stimulating factors in primary hematologic disorders. , 1992, Cancer.

[13]  R. Frenck,et al.  Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Demetri,et al.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.

[15]  L. To,et al.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.

[16]  J. Bussel,et al.  High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. , 1990, The Journal of pediatrics.

[17]  H. Broxmeyer,et al.  Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Experimental hematology.

[18]  W. Piacibello,et al.  Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.

[19]  M. Loken,et al.  Simultaneous analysis of DNA content and surface antigens in human bone marrow. , 1988, Cytometry.

[20]  C. Civin,et al.  Assessment of proliferation during maturation of the B lymphoid lineage in normal human bone marrow. , 1988, Blood.

[21]  D. Printz,et al.  Is CD33 a differentiation marker? , 1994, Progress in clinical and biological research.

[22]  D. Clapp,et al.  Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential. , 1994, Experimental hematology.

[23]  R. Benjamin,et al.  Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. , 1994, Experimental hematology.

[24]  F. Lacombe,et al.  Cytokine-mediated expansion of 5-FU resistant peripheral blood stem cells and bone marrow: self-renewal and commitment capacity. , 1994, Journal of hematotherapy.

[25]  S. Serke,et al.  Characterization and measurement of CD34-expressing hematopoietic cells. , 1994, Journal of hematotherapy.

[26]  D. Printz,et al.  Rapid discrimination of early CD34+ myeloid progenitors using CD45-RA analysis. , 1993, Blood.

[27]  H. Snoeck,et al.  Quantitative cell-cycle progression analysis of the first three successive cell cycles of granulocyte colony-stimulating factor and/or granulocyte-macrophage colony-stimulating factor-stimulated human CD34+ bone marrow cells in relation to their colony formation. , 1993, Blood.

[28]  H. Broxmeyer,et al.  Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. , 1993, Blood.

[29]  L. Kanz,et al.  Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. , 1993, European Journal of Cancer.

[30]  C. Civin,et al.  Initiation in DNA synthesis by colony-stimulating factors in subsets of human CD34+ marrow cells. , 1991, Experimental hematology.

[31]  W. Sheridan,et al.  The role of colony-stimulating factors in bone marrow transplantation. , 1991, Cancer investigation.

[32]  C. Haanen,et al.  Simultaneous measurement of DNA content and cell-surface immunofluorescence of human bone marrow cells using a single laser flow cytometer. , 1990, Cytometry.

[33]  Z. Darżynkiewicz Differential staining of DNA and RNA in intact cells and isolated cell nuclei with acridine orange. , 1990, Methods in cell biology.

[34]  A. Pollack,et al.  Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. , 1990, Methods in cell biology.

[35]  D. Williams,et al.  Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. , 1988, Experimental hematology.